Bahija Jallal (Source: MedImmune)
Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round
Immunocore — once a darling of the now-disgraced Neil Woodford — is shaking off its past by raising more than $130 million in a Series B haul.
The Oxfordshire, UK-based company, which launched in 2015 to advance its T cell receptor (TCR) technology with a mammoth $320 million round, was soon glorified with a valuation of nearly $1 billion (£800m). That unicorn status proved to be its Achilles heel, triggering an exodus of top management in recent years as potential investors balked at the old valuation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
